Memorial Sloan Kettering Cancer Center, New York, NY; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Memorial Sloan Kettering Cancer Center, New York, NY.
Clin Genitourin Cancer. 2019 Aug;17(4):e745-e750. doi: 10.1016/j.clgc.2019.03.022. Epub 2019 May 16.
The use of multiparametric magnetic resonance imaging (mpMRI) to assess prostate cancer (PCa) has increased over the past decade. We aimed to assess if preoperative mpMRI lesion score, a variable routinely available for men undergoing pre-biopsy MRI, improves the performance of commonly used preoperative predictive models for PCa recurrence.
We analyzed data from 372 patients with PCa treated with radical prostatectomy in 2012 to 2017 and assessed with pre-biopsy mpMRI within 6 months prior to surgery. Suspicious areas for cancer were scored on a standardized 5-point scale. Cox regression was used to assess the association between mpMRI score and the risk of postoperative biochemical recurrence. Two different models were tested accounting for factors included in the Kattan nomogram and in the D'Amico risk-classification.
Overall, 53% and 30% of patients were found with a lesion scored 4 or 5 at pre-biopsy mpMRI, respectively. Risk varied widely by mpMRI (29% 2-year risk of biochemical recurrence for a score of 5 vs. 5% for a score of 1-2), and mpMRI score was associated with large hazard ratios after adjusting for stage, grade, and prostate-specific antigen: 1.66, 1.96, and 2.71 for scores 3, 4, and 5, respectively. However, 95% confidence intervals were very wide (0.19-14.20, 0.26-14.65, and 0.36-20.55, respectively) and included 1.
Our data did not show that preoperative models, commonly used to assess PCa risk, were improved after including the pre-biopsy mpMRI score. However, the value of pre-biopsy mpMRI to improve preoperative risk models should be investigated in larger data sets.
在过去的十年中,使用多参数磁共振成像(mpMRI)来评估前列腺癌(PCa)的应用有所增加。我们旨在评估在接受前列腺活检前 MRI 检查的男性中,常规获得的术前 mpMRI 病变评分是否可以提高常用于 PCa 复发的术前预测模型的性能。
我们分析了 2012 年至 2017 年接受根治性前列腺切除术治疗的 372 例 PCa 患者的数据,并在手术前 6 个月内进行了前列腺活检前 mpMRI 评估。可疑癌症区域按标准化的 5 分制进行评分。使用 Cox 回归评估 mpMRI 评分与术后生化复发风险之间的关联。测试了两种不同的模型,分别考虑了 Kattan 列线图和 D'Amico 风险分类中包含的因素。
总体而言,53%和 30%的患者在前列腺活检前 mpMRI 上分别发现病变评分为 4 或 5。风险因 mpMRI 而异(评分 5 时,2 年生化复发风险为 29%,评分为 1-2 时为 5%),并且在调整分期、分级和前列腺特异性抗原后,mpMRI 评分与较大的危险比相关:评分 3、4 和 5 时,危险比分别为 1.66、1.96 和 2.71。然而,95%置信区间非常宽(分别为 0.19-14.20、0.26-14.65 和 0.36-20.55),并包括 1。
我们的数据表明,包括术前 mpMRI 评分在内,通常用于评估 PCa 风险的术前模型并没有得到改善。然而,应在更大的数据集调查术前 mpMRI 评分对改善术前风险模型的价值。